Journal
NATURE REVIEWS CANCER
Volume 14, Issue 11, Pages 722-735Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3838
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC), Australia
- NHMRC [1003929]
Ask authors/readers for more resources
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarconna suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available